ITMI20010733A0 - Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria - Google Patents

Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria

Info

Publication number
ITMI20010733A0
ITMI20010733A0 IT2001MI000733A ITMI20010733A ITMI20010733A0 IT MI20010733 A0 ITMI20010733 A0 IT MI20010733A0 IT 2001MI000733 A IT2001MI000733 A IT 2001MI000733A IT MI20010733 A ITMI20010733 A IT MI20010733A IT MI20010733 A0 ITMI20010733 A0 IT MI20010733A0
Authority
IT
Italy
Prior art keywords
isoenzine
cox
inhibitors
treatment
urinary incontinence
Prior art date
Application number
IT2001MI000733A
Other languages
English (en)
Inventor
Amedeo Leonardi
Rodolfo Testa
Luciano Guarneri
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Priority to IT2001MI000733A priority Critical patent/ITMI20010733A1/it
Publication of ITMI20010733A0 publication Critical patent/ITMI20010733A0/it
Priority to US09/969,538 priority patent/US6440963B1/en
Priority to JP2002578966A priority patent/JP2004531514A/ja
Priority to HU0303908A priority patent/HUP0303908A2/hu
Priority to IL15805002A priority patent/IL158050A0/xx
Priority to AU2002253181A priority patent/AU2002253181B2/en
Priority to CNA028078101A priority patent/CN1688315A/zh
Priority to PL02364465A priority patent/PL364465A1/xx
Priority to PCT/EP2002/003850 priority patent/WO2002080927A1/en
Priority to MXPA03008966A priority patent/MXPA03008966A/es
Priority to RU2003132445/15A priority patent/RU2003132445A/ru
Priority to BR0208694-8A priority patent/BR0208694A/pt
Priority to CA002443031A priority patent/CA2443031A1/en
Priority to KR10-2003-7012891A priority patent/KR20030087046A/ko
Priority to EP02722290A priority patent/EP1381369A1/en
Publication of ITMI20010733A1 publication Critical patent/ITMI20010733A1/it
Priority to ZA200307731A priority patent/ZA200307731B/xx
Priority to NO20034473A priority patent/NO20034473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IT2001MI000733A 2001-04-05 2001-04-05 Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria ITMI20010733A1 (it)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IT2001MI000733A ITMI20010733A1 (it) 2001-04-05 2001-04-05 Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US09/969,538 US6440963B1 (en) 2001-04-05 2001-10-01 Use of selective COX-2 inhibitors for the treatment of urinary incontinence
EP02722290A EP1381369A1 (en) 2001-04-05 2002-04-05 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
PCT/EP2002/003850 WO2002080927A1 (en) 2001-04-05 2002-04-05 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
MXPA03008966A MXPA03008966A (es) 2001-04-05 2002-04-05 Uso de inhibidores selectivos de ciclooxigenasa-2 para el tratamiento de incontinencia urinaria.
IL15805002A IL158050A0 (en) 2001-04-05 2002-04-05 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
AU2002253181A AU2002253181B2 (en) 2001-04-05 2002-04-05 Use of selective COX-2 inhibitors for the treatment of urinary incontinence
CNA028078101A CN1688315A (zh) 2001-04-05 2002-04-05 用选择性cox－2抑制剂治疗尿失禁
PL02364465A PL364465A1 (en) 2001-04-05 2002-04-05 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
JP2002578966A JP2004531514A (ja) 2001-04-05 2002-04-05 尿失禁の処置のための選択的ｃｏｘ−２阻害剤の使用
HU0303908A HUP0303908A2 (hu) 2001-04-05 2002-04-05 Szelektív COX-2 inhibitorok alkalmazása inkontinencia kezelésére szolgáló gyógyszerkészítmény előállítására
RU2003132445/15A RU2003132445A (ru) 2001-04-05 2002-04-05 Применение селективных ингибиторов сох-2 для лечения недержания мочи
BR0208694-8A BR0208694A (pt) 2001-04-05 2002-04-05 Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
CA002443031A CA2443031A1 (en) 2001-04-05 2002-04-05 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
KR10-2003-7012891A KR20030087046A (ko) 2001-04-05 2002-04-05 요실금 치료에서 선택적 ｃｏｘ-2 억제물질의 용도
ZA200307731A ZA200307731B (en) 2001-04-05 2003-10-03 Use of selective COX-2inhibitors for the treatment of urinary incontinence.
NO20034473A NO20034473L (no) 2001-04-05 2003-10-06 Anvendelse av selektive cox-2-inhibitorer ved behandling av urininkontinens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI000733A ITMI20010733A1 (it) 2001-04-05 2001-04-05 Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria

Publications (2)

Publication Number Publication Date
ITMI20010733A0 true ITMI20010733A0 (it) 2001-04-05
ITMI20010733A1 ITMI20010733A1 (it) 2002-10-05

Family

ID=11447449

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001MI000733A ITMI20010733A1 (it) 2001-04-05 2001-04-05 Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria

Country Status (17)

Country Link
US (1) US6440963B1 (it)
EP (1) EP1381369A1 (it)
JP (1) JP2004531514A (it)
KR (1) KR20030087046A (it)
CN (1) CN1688315A (it)
AU (1) AU2002253181B2 (it)
BR (1) BR0208694A (it)
CA (1) CA2443031A1 (it)
HU (1) HUP0303908A2 (it)
IL (1) IL158050A0 (it)
IT (1) ITMI20010733A1 (it)
MX (1) MXPA03008966A (it)
NO (1) NO20034473L (it)
PL (1) PL364465A1 (it)
RU (1) RU2003132445A (it)
WO (1) WO2002080927A1 (it)
ZA (1) ZA200307731B (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915992A1 (en) * 2002-02-19 2008-04-30 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
WO2003070233A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US7232821B2 (en) * 2002-04-08 2007-06-19 Glaxo Group Limited (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
EP1400243A1 (en) * 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7572922B2 (en) * 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US20050075359A1 (en) * 2003-03-14 2005-04-07 Rikako Kono Large conductance calcium-activated K channel opener
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
GB0323584D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
US20070060629A1 (en) * 2003-10-17 2007-03-15 Yasuhiro Imanishi Large conductance calcium-activated k channel opener
GB0410121D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds
AU2005252183B2 (en) * 2004-06-04 2008-07-17 Merck Sharp & Dohme Corp. Pyrazole derivatives, compositions containing such compounds and methods of use
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
US8575338B2 (en) 2008-04-09 2013-11-05 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
US20160067238A1 (en) 2013-05-06 2016-03-10 Philip Wu Pharmaceutical composition and uses thereof
CN108690078A (zh) * 2017-03-29 2018-10-23 江苏恒瑞医药股份有限公司 一种苯并塞嗪磷酸酯衍生物、其制备方法及其在医药上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4318791A (en) 1977-12-22 1982-03-09 Ciba-Geigy Corporation Use of aromatic-aliphatic ketones as photo sensitizers
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3103372A1 (de) 1981-01-27 1982-09-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue indanyl-derivate, ihre herstellung und verwendung
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
RU2139281C1 (ru) 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DE69715173T2 (de) 1996-03-29 2003-05-08 Merck Frosst Canada Inc Bisarylcyclobutenderivate als cyclooxygenasehemmer
EP0892791B1 (en) 1996-04-12 2003-03-05 G.D. Searle & Co. N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
IT1288123B1 (it) 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
EP1007515A1 (en) 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
EP1309328A4 (en) * 2000-06-20 2006-02-08 Arthur L Herbst COX-2 INHIBITORS AND PREVENTION OF SIDE EFFECTS OF RADIOTHERAPY
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists

Also Published As

Publication number Publication date
JP2004531514A (ja) 2004-10-14
PL364465A1 (en) 2004-12-13
ZA200307731B (en) 2004-09-13
AU2002253181B2 (en) 2005-02-17
HUP0303908A2 (hu) 2004-04-28
IL158050A0 (en) 2004-03-28
MXPA03008966A (es) 2004-10-15
WO2002080927A1 (en) 2002-10-17
RU2003132445A (ru) 2005-03-10
CA2443031A1 (en) 2002-10-17
US6440963B1 (en) 2002-08-27
EP1381369A1 (en) 2004-01-21
BR0208694A (pt) 2004-03-30
KR20030087046A (ko) 2003-11-12
NO20034473L (no) 2003-12-05
CN1688315A (zh) 2005-10-26
ITMI20010733A1 (it) 2002-10-05
NO20034473D0 (no) 2003-10-06

Similar Documents

Publication Publication Date Title
ITMI20010733A0 (it) Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
PL372395A1 (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1416995A4 (en) FILTERATION FLUID STERILIZATION DEVICE AND METHOD OF USE
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
EP1448218A4 (en) BETA SECRETASE INHIBITORS AND METHODS OF USE
EE200300396A (et) Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
PT1413305E (pt) Derivados aril (ou heteroaril) azolilcabrinol para o tratamento de incontinencia urinaria
AU2002255243A1 (en) Device for aiding urination and method of use thereof
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
ITPD20020251A1 (it) Dispositivo per l'ottimizzazione dell'innesto di
ITMI20011633A0 (it) Uso di polisaccaridi batterici supersolfatati inibitori dell'hiv
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
PL369826A1 (en) 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
PT1363614E (pt) Utilizacao de 2-amino-1-(4-hidroxi-3-metanossulfonamidofenil) etanol para o tratamento de incontinencia urinaria
FR2843304B1 (fr) Extraits de sangsues pour stents
ITMI20021281A1 (it) Composizioni metodi d'impiego e procedimenti di preparazione di fosfolidi metabolici insaturi
AU2003283153A8 (en) Pharmaceutical compositions for the treatment of urinary incontinence
NO20033368L (no) Nye alkyl-fenylimino-imidazolidin-derivater for behandling av urin-inkontinens
ITMI20021205A0 (it) Uso di proteine per il trattamento della leishmaniosi
ITTO20010147A0 (it) Dispositivo per l'applicazione di protesi fonatorie.